We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

35 hedge funds and large institutions have $10.8M invested in Axsome Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

351% more call options, than puts

Call options by funds: $284K | Put options by funds: $63K

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

0% more funds holding

Funds holding: 35 → 35 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.63% less ownership

Funds ownership: 13.46% → 12.84% (-0.63%)

12% less capital invested

Capital invested by funds: $12.2M → $10.8M (-$1.4M)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
5
Reduced
10
Closed
10
Calls
$284K
Puts
$63K
Net Calls
+$221K
Net Calls Change
+$214K

Top Buyers

1
ACM
Alethea Capital Management
Washington
+$1.19M
2
Millennium Management
Millennium Management
New York
+$1.02M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$823K
4
ECM
Endurant Capital Management
California
+$375K
5
OAM
Oxford Asset Management
United Kingdom
+$243K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.44M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$770K
3
OPPM
Opus Point Partners Management
New York
-$415K
4
JP Morgan Chase
JP Morgan Chase
New York
-$140K
5
SCM
Sio Capital Management
New York
-$117K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Alethea Capital Management
Washington
$2.56M +$1.19M +360,986 +66%
Stifel Financial
2
Stifel Financial
Missouri
$1.14M – – –
SCM
3
Sio Capital Management
New York
$1.07M -$117K -35,646 -9%
Vanguard Group
4
Vanguard Group
Pennsylvania
$955K -$770K -233,997 -41%
RA
5
Royce & Associates
New York
$937K – – –
Millennium Management
6
Millennium Management
New York
$871K +$1.02M +308,802 New
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$705K +$823K +250,000 New
ECM
8
Endurant Capital Management
California
$590K +$375K +114,010 +120%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$265K – – –
Jacobs Levy Equity Management
10
Jacobs Levy Equity Management
New Jersey
$237K +$68.4K +20,800 +33%
OAM
11
Oxford Asset Management
United Kingdom
$208K +$243K +73,713 New
BlackRock
12
BlackRock
New York
$181K +$26.8K +8,137 +15%
BCM
13
Bridgeway Capital Management
Texas
$178K -$82.3K -25,000 -28%
Mariner
14
Mariner
Kansas
$117K – – –
SIM
15
Spark Investment Management
New York
$115K +$135K +40,900 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$98K +$114K +34,690 New
WVP
17
Worth Venture Partners
New Jersey
$96K -$18.3K -5,552 -14%
Northern Trust
18
Northern Trust
Illinois
$86K – – –
BWP
19
Baldwin Wealth Partners
Massachusetts
$82K -$4.31K -1,310 -4%
SAMH
20
Shanda Asset Management Holdings
British Virgin Islands
$56K – – –
Renaissance Technologies
21
Renaissance Technologies
New York
$43K +$49.7K +15,110 New
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$37K +$43.7K +13,284 New
Barclays
23
Barclays
United Kingdom
$30K +$34.5K +10,500 New
Group One Trading
24
Group One Trading
Illinois
$28K -$10.2K -3,101 -24%
Wells Fargo
25
Wells Fargo
California
$26K -$6.58K -2,000 -18%
1
2

AXSM Hedge Fund Activity: Q4 2018 in Review

35 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2018, worth a combined $10.8M — down 12% from $12.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new AXSM positions and 10 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.

The largest buyer was Alethea Capital Management, adding an estimated $1.19M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.44M sold.

  • 35 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $10.8M of Axsome Therapeutics stock for Q4 2018, down 12% quarter-over-quarter.
  • 11 funds opened new Axsome Therapeutics positions in Q4 2018 and 10 closed out, a net change of +1 holder.
  • The largest Axsome Therapeutics buyer in Q4 2018 was Alethea Capital Management, an estimated $1.19M added.
  • The largest Axsome Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $1.44M sold.

Based on aggregated 13F filings for Q4 2018.